Telomir Pharma Gets FDA Nod for Breast Cancer Drug Trial

Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer. This clearance enables the initiation of a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing, and preliminary antitumor activity. The trial is supported by preclinical pharmacology, toxicology, and biomarker data as the Company advances its lead candidate toward clinical development. Telomir-Zn is a small-molecule therapeutic that targets fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.

The news was disseminated via BioMedWire, a specialized communications platform within the IBN Dynamic Brand Portfolio, which provides access to a vast network of wire solutions, article syndication to 5,000+ outlets, and social media distribution. For more information, investors can visit the company's newsroom at https://ibn.fm/TELO. BioMedWire is where breaking news, insightful content, and actionable information converge, serving private and public companies in the biotechnology and life sciences sectors. The full press release is available at https://ibn.fm/p4e9J.

This FDA clearance marks a significant milestone for Telomir Pharmaceuticals, as it moves from preclinical to clinical development. Triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options, making the potential of Telomir-Zn particularly noteworthy. The company's focus on epigenetic and metabolic mechanisms offers a novel approach that could address unmet medical needs. With the trial set to begin, Telomir Pharmaceuticals is poised to generate crucial data on the safety and efficacy of its lead candidate, potentially paving the way for new therapeutic options for patients with advanced or metastatic triple-negative breast cancer.